FOLR1 and ovarian cancer: In addition, the phase III RAINFOL-02 study (NCT06619236) is ongoing, evaluating Rina-S in patients with platinum-resistant ovarian cancer compared to the investigator’s choice of treatment, while in 2024, Rina-S received a Fast Track designation from the FDA for FRα-positive platinum-resistant high-grade serous or endometrioid ovarian cancer [111].